According to Finnish biotechnology company Herantis Pharma, the European Innovation Council (EIC) will pay the predefined milestone payment for the two-year grant project entitled Revolutionary therapeutic treatment for stopping progression of Parkinson's disease (ReTreatPD). Herantis Pharma and EIC signed an EIC Accelerator agreement for a EUR 2.5mn grant for the ReTreatPD project in April 2023. Herantis Pharma received EUR 1.4mn in prefinancing in May 2023. ReTreatPD focuses on preparations towards a Phase 2 clinical study with HER-096 in Parkinson's disease. HER-096, an engineered peptidomimetic molecule, is Herantis Pharma's lead product.